Search

Events
MEMBERS
TOPICS
REGIONS
Bridging Science, Advocacy, and Practice: A Unified Approach to Combatting Antimicrobial Resistance

Bridging Science, Advocacy, and Practice: A Unified Approach to Combatting Antimicrobial Resistance

The Infectious Disease Alliance (ID Alliance) will host a hybrid event titled “Bridging Science, Advocacy, and Practice: A Unified Approach to Combating Antimicrobial Resistance,” taking place in Statens Serum Institut (SSI) Campus, Copenhagen, Denmark, and online via Teams. This event will bring together global experts, policymakers, researchers, and advocates to explore collaborative approaches for addressing antimicrobial resistance (AMR) as a growing global challenge that cuts across human health, animal health, agriculture, and the environment.

Tackling AMR with Outcomes-Based Financing: Findings from Tanzania and Senegal

Tackling AMR with Outcomes-Based Financing: Findings from Tanzania and Senegal

On February 25, Neha Agarwal, senior director of strategy at PATH and Alliance board vice chair, led a session for Stanford Mussallem Center for Biodesign’s Innovation and Health Equity Series. She discussed how outcomes-based financing (OBF) can be leveraged to tackle antimicrobial resistance (AMR). Her talk, which provided a first look at data from a year-long study in Tanzania and Senegal, emphasized how innovative financing mechanisms could reshape global health strategies.

Outcomes-Based Finance as a Tool for Health Equity and Innovation

Outcomes-Based Finance as a Tool for Health Equity and Innovation

Join Stanford Mussallem Center for Biodesign on February 25 for the next session in their Innovation and Health Equity Discussion Series where Neha Agarwal, senior director of strategy at PATH and Alliance board vice chair, will discuss an innovative outcomes-based financing (OBF) mechanism being developed in partnership with the governments of Tanzania and Senegal, the Bay Area Global Health Alliance, and Pfizer to reinforce antimicrobial stewardship efforts in LMICs.

PATH, Pfizer, and the Bay Area Global Health Alliance Partner to Combat Antimicrobial Resistance in Senegal and Tanzania Using an Outcomes-Based Financing Mechanism

PATH, Pfizer, and the Bay Area Global Health Alliance Partner to Combat Antimicrobial Resistance in Senegal and Tanzania Using an Outcomes-Based Financing Mechanism

During the Clinton Global Initiative (CGI) 2024 Annual Meeting, PATH, in partnership with the Bay Area Global Health Alliance and Pfizer, announced a Commitment to Action: Outcomes-Based Financing as a Tool to Curb AMR in LMICs. This commitment aims to combat antimicrobial resistance (AMR) and incentivize antimicrobial stewardship (AMS) through an innovative outcomes-based financing mechanism.

UNGA79

UNGA79

The 79th session of the UN General Assembly (UNGA 79) will open on Tuesday, 10 September 2024. The first day of the high-level General Debate will be Tuesday, 24 September 2024. When global leaders meet at the UN, they will confront yet another year of complex crises and conflicts — as a deeply divided world watches. The UN is the only place on Earth where countries — whether big or small — have a say. The debates and conversations that will unfold during UNGA 79 will shape the solutions that can redefine our future. UNGA 79 will also include High-level Meetings on two issues of existential importance: Antimicrobial resistance (AMR) and the global threat of sea-level rise.

UC Davis: Rx One Health Field Institute

UC Davis: Rx One Health Field Institute

Novel pathogens, climate change, biodiversity loss, food insecurity, health disparities, antimicrobial resistance, water scarcity, pollution… our planet faces a host of interrelated serious challenges in the Anthropocene era. The Rx One Health Field Institute at Alliance member UC Davis is a transformative field-based experiential learning course focused on One Health core competencies for graduate students and early career professionals from all disciplines.